Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.
In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...
AbbVie received FDA approval for a first in class, all oral, fixed duration regimen combining VENCLEXTA and acalabrutinib for ...
The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.Acalabrutinib (Calquence, AstraZeneca) tablets ...
AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...
Data Trends provide quick, visually memorable data-driven information and insights that are useful in clinical practice. Here, we explore recent treatment updates in chronic lymphocytic leukemia (CLL) ...
The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.
Richter transformation develops in 2%–10% of CLL cases, often with rapid clinical decline, limited chemotherapy efficacy, and ...
The FDA approved acalabrutinib (Calquence) plus venetoclax (Venclexta) for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma as the first all-oral, fixed-duration ...
To overcome the challenges of current CAR T-cell strategies and enhance their efficacy and specificity for acute myeloid leukemia, researchers at the Sino-American Cancer Foundation and collaborating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results